Stockpolly
Search
ANRO · NYSE · Biotechnology

Alto Neuroscience (ANRO)

Develops neuropsychiatric drug candidates for biomarker-defined patient populations.

$36.64
Pre-market+0.05 (+0.14%)
At close$36.59(+3.95%)
Watchlist

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
estimated · in 69 days
EPS estimate
−$0.67
Revenue estimate
—
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.56−$0.53−$0.65−$0.52−$0.45−$0.80−$0.65Pending
Estimate−$0.65−$0.59−$0.57−$0.66−$0.56−$0.56−$0.73−$0.67
Surprise+13.8%+10.2%−14.0%+21.2%+19.6%−42.9%+11.5%—

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————

History

DateEstimateReportedSurprise
Nov 2026−$0.67——
Aug 2026−$0.73−$0.65+11.5%
May 2026−$0.56−$0.80−42.9%
Mar 2026−$0.56−$0.45+19.6%
Nov 2025−$0.66−$0.52+21.2%

The latest year is open to everyone — the 11 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Feb 2024
Jun 2023
Mar 2023
Dec 2022
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.67——————
Aug 12, 2026−$0.73−$0.65+11.5%———+10.7%
May 13, 2026−$0.56−$0.80−42.9%———+3.2%
Mar 16, 2026−$0.56−$0.45+19.6%———−8.0%
Nov 12, 2025−$0.66−$0.52+21.2%———−20.1%

The latest year is open to everyone — the 11 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 14, 2025
Mar 20, 2025
Nov 12, 2024
Aug 13, 2024
May 14, 2024
Mar 21, 2024
Feb 5, 2024
Jun 29, 2023
Mar 31, 2023
Dec 31, 2022